Do I need to stop a GLP-1 before pregnancy?

Two separate issues arise here and they are often confused. The first is that GLP-1 medications should not be continued in pregnancy. The second is that starting one can make an unplanned pregnancy more likely, both because tirzepatide interferes with oral contraception and because weight loss itself restores ovulation in many women.

Stopping before a planned pregnancy

The Wegovy label states that females of reproductive potential taking semaglutide for weight reduction or cardiovascular risk reduction should discontinue at least two months before they plan to become pregnant, to account for the long half life of the drug. Both the Wegovy and Zepbound labels instruct that the medication be stopped when a pregnancy is recognised, and both state that weight loss offers no benefit to a pregnant patient and may cause fetal harm. The WHO's December 2025 guideline explicitly excludes pregnant women from its recommendation.

The contraception interaction with tirzepatide

Tirzepatide delays gastric emptying enough to reduce absorption of oral hormonal contraceptives. The Zepbound label advises patients using oral hormonal contraception to switch to a non-oral method, or to add a barrier method, for four weeks after starting tirzepatide and for four weeks after each dose escalation. That is a long window across a full titration, and it is one of the most commonly missed instructions on the label. A hormonal intrauterine device, implant or injection avoids the problem entirely.

Why fertility often returns faster than expected

Weight loss restores ovulation in a substantial proportion of women with anovulatory cycles, particularly in polycystic ovary syndrome. Women who have been told for years that they cannot conceive can find themselves pregnant within months of starting treatment. If pregnancy is not wanted, contraception has to be in place before the first injection, not discussed afterwards. If pregnancy is wanted, the sequence matters: reach a stable weight, stop the medication, allow the washout, then try.

What is known about accidental exposure

Observational data are reassuring but limited. Cohort studies of GLP-1 exposure in early pregnancy have not shown an increased risk of major congenital malformations compared with insulin, but those studies were done in women with pre-existing type 2 diabetes rather than in weight management, the numbers exposed are small, and the estimates are imprecise. An accidental exposure is a reason to inform your obstetric team promptly, not a reason to panic.

If you are of reproductive age, settle three things before the first dose: what contraception you are using, whether it is affected by the drug, and what your pregnancy plans are over the next two years. That conversation takes five minutes and prevents most of the problems in this area.